Prostate Cancer

An expert answers prostate cancer questions from a recent CURE Educated Patient Summit.

From “The Office” star opening up in a new interview to Charley Steiner revealing his multiple myeloma journey, here is this week’s cancer news.

Meta: ONCT-534 had a well-tolerated safety profile on a twice daily dosing schedule in relapsed/refractory metastatic castration-resistant prostate cancer.

Patients with prostate cancer may differ in time to testosterone recovery, depending on the length of treatment and age, but takes six months on average.

It’s crucial for patients with prostate cancer to know that all treatments come with side effects, which may affect their quality of life.

The rate at which PSA rises after hormonal therapy for prostate cancer is a key factor in determining the effectiveness of the treatment.

With approaches like high intensity focused ultrasound, patients with prostate cancer may experience lower rates of urinary incontinence and erectile dysfunction, an expert said.

Patients with metastatic prostate cancer may have improved survival outcomes after undergoing next-generation PSMA PET imaging, an expert explained.

As part of the CURE® Educated Patient® Prostate Cancer Summit, an expert discussed the role genetic testing plays in treatment decision-making for many.

TULSA is a targeted prostate cancer treatment that uses ultrasound to destroy tumors while preserving healthy tissue.

Two patients reflected on how extraordinary their oncology nurses are — even noting that they forget about their cancer when talking with their nurses.

An expert answered CURE® readers’ questions on several aspects of a prostate cancer journey, including treatment options and sexual function.

The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer.

Patients with metastatic, castration-resistant prostate cancer saw significant benefits from the combination of Xofigo and Xtandi.

From Princess Kate entering ‘a new phase of recovery’ to a Rock and Roll Hall of Famer’s blood cancer announcement, here’s what’s happening in the cancer space this week.

Researchers have compared Xtandi and Zytiga head-to-head in the treatment of metastatic castration-resistant prostate cancer.

From Danielle Fishel and Rick Steves announcing their diagnosis to the “Emily in Paris” star discussing her cancer experience, here’s what’s happening in the oncology space this week.

Androgen receptor pathway inhibitors were shown to better treat patients with metastatic castration-resistant prostate cancer and improved survival.

I wrote this letter to cancer because my brother died too early.

My wife and children were by my side as I underwent grueling and life-changing prostate cancer treatment.

When compared with Zytiga, Xtandi appeared to have a lower incidence of infection among men with prostate cancer, especially those under 70 years.

Nubeqa plus androgen deprivation therapy displayed positive radiological progression-free survival results in early trial data.

Patients with favorable-risk prostate cancer “should be aware that they don't need treatment right away,” one expert said.

During my "watch and wait" time for prostate cancer, I spend this time wisely on things like attending writing webinars.

Leaning on spiritual belief may strengthen patients' life purposes, but for many, it's common to temporarily loosen their grip on faith after a cancer diagnosis.

As part of the “Speaking Out” series, a radiation oncologist discusses the benefits of MRI-guided stereotactic body radiation therapy.

From the NBA’s Alonzo Mourning opening up about his prostate surgery to an actor from “Felicity” dying of cancer, here’s what is happening in the oncology space this week.

Two years of postsurgical androgen deprivation therapy resulted in a 10-year metastasis-free survival rate of nearly 80%.

Treatment with Pluvicto following ARPI resulted in favorable progression and response outcomes in PSMA-positive mCRPR.